Category: Life-cycle development

Life-cycle development Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)

Life-cycle development Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland

Life-cycle development Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs

Life-cycle development Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets

Life-cycle development Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia